| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_058c498ce4e3dd63f7a04956860c0ff5 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-145 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate |
2019-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e45529d48f9b8e1a54ba058e38cbb259 |
| publicationDate |
2021-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2019360638-A1 |
| titleOfInvention |
Dosage regime |
| abstract |
The present disclosure relates to use of cysteamine, formulations comprising cysteamine and pharmaceutically acceptable salts of cysteamine in the treatment of cystic fibrosis and conditions associated with cystic fibrosis. |
| priorityDate |
2018-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |